Canadian Biomaterials Society
La Société Canadienne des Biomatériaux

Dear CBS Members, As you are aware, the COVID-19 pandemic has caused numerous disruptions around the world, and scheduled conferences are being either postponed or canceled...

We are very pleased to inform you that Dr. Paul Santerre has been selected by the Board of Directors of the Canadian Biomaterials Society CBS as the next recipient of the CBS Lifetime Achievement Award , acknowledging his outstanding contributions to our Society...

CBS is pleased to offer travel awards to assist students and post-doctoral fellows who are CBS members to present their accepted oral or poster abstracts at the 11th World Biomaterials Congress this May in Glasgow, Scotland...

The Fall 2019 edition of the CBS Newsletter is now available. Read about the latest initiatives from CBS, look back at the Quebec City CBS Annual Meeting and look ahead to WBC 2020 coming up this May in Glasgow, find out more about our very active student chapters across the country, meet the new CBS Senior Board Members and President-Elect, and learn more about the many award opportunities provided by CBS...

Fibrin is a natural biodegradable, non-toxic and non-immunogenic polymer 1 . It has been widely used in tissue engineering and cell culture to test different cell types attachments...

Skull bone fractures and deformities are caused by a variety of conditions including Traumatic Brain Injury TBI or congenital conditions involving suture fusion...

Polylactic acid PLA is a biodegradable aliphatic polyester, which is widely used in the pharmaceutical and biomedical sectors on account of its biocompatibility and good mechanical properties...

Biodegradable metals, a new class of biomaterials, are promising in stenting applications. In the past years, Fe-Mn based alloys have raised the interest of the scientific community due to good combination of properties such as mechanical properties, biocompatibility and corrosion behavior...

Systemic adoptive T lymphocyte transfer is an emerging cancer immunotherapy showing tremendous promise in clinical studies, and its success lies in the ability of the antigen-experienced cytotoxic T lymphocytes cTL to access and to persist in the tumour microenvironment 1 ...